During this segment, the panelists explore the use of personalized medicine in castration-resistant prostate cancer.
Jeffrey D. Dunn, PharmD, MBA, and Raoul S. Concepcion, MD, explain that clinicians hope to have better data available in the future to provide definitive answers about treatment options for specific patient populations.
Dr Concepcion explains the variables that are being reviewed to help clinicians make wiser treatment decisions for their patients.
However, E. David Crawford, MD, reminds the panelists why achieving this goal will not be easy.
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Demographic Disparities in Video Visit Telemetry: Understanding Telemedicine Utilization
March 7th 2025A stratified demographics analysis of video visit telemetry data reveals that age older than 65 years and African American/Black race are associated with higher video visit failure rates, whereas language, sex, and ethnicity are not.
Read More